Download PDF
Horm Metab Res 2022; 54(10): 686-695
DOI: 10.1055/a-1929-1677
Original Article: Endocrine Care

Associations of PNPLA3 rs738409 Polymorphism with Plasma Lipid Levels: A Systematic Review and Meta-Analysis

Zhi Luo 
1   Cardiology, Zhongnan Hospital of Wuhan University, Wuhan, China
,
Yang Liu
2   Endocrinology, China Resources and WISCO General Hospital, Wuhan, China
,
Hang Li
3   Geratology, Zhongnan Hospital of Wuhan University, Wuhan, China
,
Yawen Zhou 
1   Cardiology, Zhongnan Hospital of Wuhan University, Wuhan, China
,
Yuanyuan Peng
1   Cardiology, Zhongnan Hospital of Wuhan University, Wuhan, China
,
Xuan Lin
2   Endocrinology, China Resources and WISCO General Hospital, Wuhan, China
,
Ying Fang
2   Endocrinology, China Resources and WISCO General Hospital, Wuhan, China
,
Jing Wan
1   Cardiology, Zhongnan Hospital of Wuhan University, Wuhan, China
4   Institute of Myocardial Injury and Repair, Wuhan University, Wuhan, China
,
Baozhu Wei
1   Cardiology, Zhongnan Hospital of Wuhan University, Wuhan, China
4   Institute of Myocardial Injury and Repair, Wuhan University, Wuhan, China
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Abstract

Accumulating evidence has shown that the rs738409 polymorphism of patatin-like phospholipase domain-containing 3 (PNPLA3) is associated with non-alcoholic fatty liver disease (NAFLD). Since NAFLD has been reported to be associated with lipid metabolism, this study is conducted to explore whether the rs738409 polymorphism of PNPLA3 was associated with lipid levels. By searching PubMed and the Cochrane database from May 31, 2020, to June 30, 2021. Sixty-three studies (81 003 subjects) were included for the analysis. The consistent findings for the associations of rs738409 polymorphism with lipid levels were the significantly decreased triglycerides (TG) (SMD=−0.04, 95% CI=−0.07 to −0.01, p=0.02) and total cholesterol (TC) (SMD=−0.03, 95% CI=−0.05 to −0.01, p<0.01) levels. Subgroup analysis indicated that the associations of rs738409 polymorphism with TG and TC levels were stronger in Caucasians, obesity patients, and adult subjects than in Asians, T2DM patients, and children subjects. The rs738409 polymorphism of PNPLA3 was associated with lower TG and TC levels in Caucasians, obese and adult subjects, which may contribute to the reduced coronary artery disease (CAD) risk between PNPLA3 rs738409 polymorphism and CAD.

Key words

PNPLA3 - rs738409 - polymorphism - lipids and cholesterol - CAD


Publication History

Received: 22 January 2022

Accepted after revision: 11 August 2022

Article published online:
07 October 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003; 37: 1202-1219
    CrossrefPubMedGoogle Scholar
  • 2 Speliotes EK, Yerges-Armstrong LM, Wu J. et al. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Gene 2011; 7: e1001324
    CrossrefPubMedGoogle Scholar
  • 3 Namjou B, Lingren T, Huang Y. et al. GWAS and enrichment analyses of non-alcoholic fatty liver disease identify new trait-associated genes and pathways across eMERGE Network. BMC Med 2019; 17: 135
    CrossrefPubMedGoogle Scholar
  • 4 Kozlitina J, Smagris E, Stender S. et al. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2014; 46: 352-356
    CrossrefPubMedGoogle Scholar
  • 5 Trépo E, Romeo S, Zucman-Rossi J. et al. PNPLA3 gene in liver diseases. J Hepatol 2016; 6: 399-412
    CrossrefPubMedGoogle Scholar
  • 6 Pingitore P, Romeo S. The role of PNPLA3 in health and disease. Biochim Biophys Acta Mol Cell Biol Lipids 2019; 1864: 900-906
    PubMedGoogle Scholar
  • 7 Baclig MO, Lozano-Kühne JP, Mapua CA. et al. Genetic variation I148M in patatin-like phospholipase 3 gene and risk of non-alcoholic fatty liver disease among Filipinos. Int J Clin Exp Med 2014; 7: 2129-2136
    PubMedGoogle Scholar
  • 8 Jenkins CM, Mancuso DJ, Yan W. et al. Identification, cloning, expression, and purification of three novel human calcium-independent phospholipase A2 family members possessing triacylglycerol lipase and acylglycerol transacylase activities. J Biol Chem 2004; 279: 48968-48975
    CrossrefPubMedGoogle Scholar
  • 9 Pingitore P, Romeo S. The role of PNPLA3 in health and disease. Biochim Biophys Acta Mol Cell Biol Lipids 2019; 1864: 900-906
    CrossrefPubMedGoogle Scholar
  • 10 Chamoun Z, Vacca F, Parton RG. et al. PNPLA3/adiponutrin functions in lipid droplet formation. Biol Cell 2013; 105: 219-233
    CrossrefPubMedGoogle Scholar
  • 11 Qiao A, Liang J, Ke Y. et al. Mouse patatin-like phospholipase domain-containing 3 influences systemic lipid and glucose homeostasis. Hepatology 2011; 54: 509-521
    CrossrefPubMedGoogle Scholar
  • 12 He S, McPhaul C, Li JZ. et al. A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. J Biol Chem 2010; 285: 6706-6715
    CrossrefPubMedGoogle Scholar
  • 13 Pirazzi C, Adiels M, Burza MA. et al. Patatin-like phospholipase domain-containing 3 (PNPLA3) I148M (rs738409) affects hepatic VLDL secretion in humans and in vitro. J Hepatol 2012; 57: 1276-1282
    CrossrefPubMedGoogle Scholar
  • 14 Kumari M, Schoiswohl G, Chitraju C. et al. Adiponutrin functions as a nutritionally regulated lysophosphatidic acid acyltransferase. Cell Metab 2012; 15: 691-702
    CrossrefPubMedGoogle Scholar
  • 15 Rüschenbaum S, Schwarzkopf K, Friedrich-Rust M. et al. Patatin-like phospholipase domain containing 3 variants differentially impact metabolic traits in individuals at high risk for cardiovascular events. Hepatol Commun 2018; 2: 798-806
    CrossrefPubMedGoogle Scholar
  • 16 Tang CS, Zhang H, Cheung CY. et al. Exome-wide association analysis reveals novel coding sequence variants associated with lipid traits in Chinese. Nat Commun 2015; 6: 10206
    CrossrefPubMedGoogle Scholar
  • 17 Yusuf S, Hawken S, Ounpuu S. et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364: 937-952
    CrossrefPubMedGoogle Scholar
  • 18 Liberati A, Altman DG, Tetzlaff J. et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 2009; 62: 1-34
    CrossrefPubMedGoogle Scholar
  • 19 Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 Updated September 2006. The Cochrane Collaboration 2006; 1-256
    PubMed
  • 20 DerSimonian R, Kacker R. Random-effects model for meta-analysis of clinical trials: an update. Contemp Clin Trials 2007; 28: 105-114
    CrossrefPubMedGoogle Scholar
  • 21 Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 1088-1101
    CrossrefPubMedGoogle Scholar
  • 22 BasuRay S, Wang Y, Smagris E. et al. Accumulation of PNPLA3 on lipid droplets is the basis of associated hepatic steatosis. Proc Natl Acad Sci U S A 2019; 116: 9521-9526
    CrossrefPubMedGoogle Scholar
  • 23 BasuRay S, Smagris E, Cohen JC. et al. The PNPLA3 variant associated with fatty liver disease (I148M) accumulates on lipid droplets by evading ubiquitylation. Hepatology 2017; 66: 1111-1124
    CrossrefPubMedGoogle Scholar
  • 24 Smagris E, BasuRay S, Li J. et al. Pnpla3I148M knockin mice accumulate PNPLA3 on lipid droplets and develop hepatic steatosis. Hepatology 2015; 61: 108-118
    CrossrefPubMedGoogle Scholar
  • 25 Hu J, Zhang Z, Shen WJ. et al. Cellular cholesterol delivery, intracellular processing and utilization for biosynthesis of steroid hormones. Nutr Metab (Lond) 2010; 7: 47
    CrossrefPubMedGoogle Scholar
  • 26 Shimobayashi SF, Ohsaki Y. Universal phase behaviors of intracellular lipid droplets. Proc Natl Acad Sci U S A 2019; 116: 25440-25445
    CrossrefPubMedGoogle Scholar
  • 27 Huang Y, Cohen JC, Hobbs HH. Expression and characterization of a PNPLA3 protein isoform (I148M) associated with nonalcoholic fatty liver disease. J Biol Chem 2011; 286: 37085-37093
    CrossrefPubMedGoogle Scholar
  • 28 Mittelstraß K, Waldenberger M. DNA methylation in human lipid metabolism and related diseases. Curr Opin Lipidol 2018; 29: 116-124
    CrossrefPubMedGoogle Scholar
  • 29 Kitamoto T, Kitamoto A, Ogawa Y. et al. Targeted-bisulfite sequence analysis of the methylation of CpG islands in genes encoding PNPLA3, SAMM50, and PARVB of patients with non-alcoholic fatty liver disease. J Hepatol 2015; 63: 494-502
    CrossrefPubMedGoogle Scholar
  • 30 Carr RM, Ahima RS. Pathophysiology of lipid droplet proteins in liver diseases. Exp Cell Res 2016; 340: 187-192
    CrossrefPubMedGoogle Scholar
  • 31 Tsai WT, Nakamura Y, Akasaka T. et al. Soyasaponin ameliorates obesity and reduces hepatic triacylglycerol accumulation by suppressing lipogenesis in high-fat diet-fed mice. J Food Sci 2021; 86: 2103-2117
    CrossrefPubMedGoogle Scholar
  • 32 WHO European Regional Obesity Report 2022. Copenhagen: WHO Regional Office for Europe; 2022. Available online https://www.who.int/europe/publications/i/item/9789289057738
  • 33 Janssen F, Bardoutsos A, Vidra N. Obesity prevalence in the long-term future in 18 European countries and in the USA. Obes Facts 2020; 13: 514-527
    CrossrefPubMedGoogle Scholar